Table 1.

Cytotoxicity profiles of glycosylated Pt(IV) complexes (IC₅₀ in μM) in seven human carcinoma cell lines.

	HeLa	MCF-7	LNCaP	PC3	HepG-2	A549	A549R	RFa
1a	0.80 ± 0.93	2.28 ± 0.56	23.83 ± 0.89	22.85 ± 1.45	3.94 ± 0.39	10.85 ± 1.98	35.78 ± 1.69	3.3
2a	11.36 ± 1.56	27.01 ± 0.34	50.78 ± 0.79	61.42 ± 0.67	50.00 ± 1.79	>100	13.40 ± 2.57	/
3a	3.96 ± 0.75	5.22 ± 2.78	16.78 ± 0.34	39.74 ± 0.76	6.64 ± 1.79	10.06 ± 1.20	39.67 ± 0.69	3.94
4a	15.78 ± 0.34	>100	22.97 ± 0.89	>100	>100	>100	29.67 ± 0.64	/
5a	3.10 ± 0.89	8.01 ± 0.56	5.23 ± 1.77	16.77 ± 1.56	6.70 ± 1.89	2.17 ± 1.68	9.96 ± 0.57	4.59
1c	18.21 ± 1.01	24.18 ± 1.44	>100	>100	11.62 ± 1.58	36.38 ± 1.39	4.26 ± 1.90	0.12
2c	4.05 ± 0.87	8.29 ± 1.87	4.70 ± 0.89	>100	59.34 ± 1.49	14.54 ± 1.47	8.37 ± 1.90	0.58
3c	0.91 ± 0.54	27.22 ± 1.56	>100	1.13 ± 0.45	3.27 ± 1.67	3.38 ± 1.49	14.64 ± 1.78	4.33
4c	>100	7.21 ± 0.78	>100	22.88 ± 0.78	10.67 ± 1.49	14.33 ± 1.48	25.20 ± 1.79	1.79
5c	32.21 ± 0.34	17.89 ± 0.12	22.12 ± 1.45	7.45 ± 0.56	>100	17.48 ± 0.89	74.08 ± 1.67	4.24
6c	16.77 ± 0.45	20.76 ± 0.45	20.10 ± 1.78	7.06 ± 0.56	50.92 ± 1.46	23.81 ± 0.78	>100	/
1d	3.10 ± 0.78	39.64 ± 0.79	/	14.33 ± 0.56	14.09 ± 1.46	10.56 ± 2.31	10.04 ± 1.69	0.95
2d	0.66 ± 0.65	0.61 ± 0.66	10.89 ± 0.89	7.86 ± 0.56	7.90 ± 1.46	0.89 ± 2.98	1.94 ± 1.69	2.18
3d	3.01 ± 0.67	45.06 ± 0.77	>100	>100	13.18 ± 1.38	1.90 ± 2.78	>100	/
4d	2.63 ± 0.78	15.55 ± 0.56	>100	>100	17.16 ± 1.46	1.94 ± 1.78	>100	/
5d	0.58 ± 0.78	0.35 ± 1.34	12.04 ± 0.79	6.27 ± 1.45	1.77 ± 1.39	2.29 ± 1.78	5.67 ± 1.69	2.48
6d	2.88 ± 0.67	0.89 ± 1.34	20.01 ± 0.79	66.62 ± 1.45	4.10 ± 1.46	29.88 ± 1.78	47.00 ± 1.69	1.57
7d	3.01 ± 0.67	1.36 ± 1.34	20.78 ± 0.79	>100	4.30 ± 1.46	36.46 ± 1.78	42.00 ± 1.69	1.15

^aRF: Resistance factor = IC₅₀(A549R)/IC₅₀(A549).